Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Is it O-K+?

<p>Hannah Brokmeier, Pharm.D. (<a href='https://twitter.com/hannahbrokmeier'>@hannahbrokmeier</a>) discusses the role of MRAs in patients with ESRD, reviews the literature concerning risks and benefits of MRAs in patients with ESRD, and outlines a potential MRA treatment regimen for a patient with dialysis-dependent ESRD.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>